Vor Biopharma Inc. (NASDAQ:VOR) Given Average Recommendation of “Moderate Buy” by Brokerages

Vor Biopharma Inc. (NASDAQ:VOR) has been given an average rating of “Moderate Buy” by the eleven analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $43.3750.

A number of research firms have weighed in on VOR. Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Wedbush raised their target price on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Vor Biopharma in a report on Monday, May 18th. Weiss Ratings raised Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Tuesday. Finally, Wall Street Zen downgraded shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th.

Institutional Trading of Vor Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. grew its stake in Vor Biopharma by 172.7% in the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after acquiring an additional 3,422,697 shares during the period. Fcpm Iii Services B.V. lifted its holdings in shares of Vor Biopharma by 852.8% in the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock worth $47,315,000 after purchasing an additional 3,237,714 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new position in shares of Vor Biopharma in the 4th quarter worth $33,275,000. Paradigm Biocapital Advisors LP acquired a new stake in Vor Biopharma in the 4th quarter valued at $22,890,000. Finally, NEXTBio Capital Management LP bought a new stake in Vor Biopharma during the 4th quarter valued at $13,080,000. 97.29% of the stock is owned by institutional investors.

Vor Biopharma Stock Up 4.3%

Shares of VOR opened at $23.29 on Friday. Vor Biopharma has a 12 month low of $6.50 and a 12 month high of $50.20. The stock’s 50-day moving average price is $18.36 and its two-hundred day moving average price is $15.96.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). As a group, research analysts anticipate that Vor Biopharma will post -2.64 earnings per share for the current fiscal year.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).